Small trial shows drug combo doubles pancreatic cancer survival

A new treatment for advanced pancreatic cancer has doubled survival times in a small but promising trial, offering fresh hope where few options previously existed. Researchers tested a combination of immunotherapy and a targeted drug in patients with late-stage disease, and found that half were still alive after 14 months—more than twice the typical survival for this aggressive cancer.

The trial, reported by NBC News, involved just over 30 patients with metastatic pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Most participants had already failed standard chemotherapy. After receiving the experimental therapy, which pairs a PD-1 inhibitor with a drug that blocks a specific cancer-driving mutation, their average survival increased to nearly 1.2 years—up from the usual 6–8 months. Two patients saw their tumors shrink significantly, and one remained cancer-free for over two years.

Why this matters: pancreatic cancer is one of the deadliest, with an overall five-year survival rate under 10%. It’s often diagnosed late, and current treatments offer limited benefit. This early success suggests a new, potentially more effective approach—especially for patients with a particular genetic profile. While the study is small and needs larger trials to confirm the results, the findings point toward a future where immunotherapy could become a standard part of pancreatic cancer care.

Doctors warn that the therapy isn’t a cure and doesn’t work for everyone. Side effects like immune overactivity were common. Still, for a disease with so few victories, even modest gains are significant. “We’re seeing signals we’ve never seen before,” said one researcher involved in the study. If confirmed, this approach could change how doctors treat advanced pancreatic cancer—and give patients precious extra time.